Brief: Arch Biopartners Announces Dosing Of First Patient In Turkey In Phase II Trial Of LSALT Peptide To Treat COVID-19 Complications
05/11/2020 13:49
Nov 5 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS ANNOUNCES DOSING OF FIRST PATIENT IN
TURKEY IN
PHASE II TRIAL OF LSALT PEPTIDE TO TREAT COMPLICATIONS FROM
COVID-19
* ARCH BIOPARTNERS INC - EXPLORING OPPORTUNITY TO ADD
CANADIAN
CLINICAL SITES TO TRIAL
* ARCH BIOPARTNERS INC - PHASE II TRIAL CONTINUES TO RECRUIT
PATIENTS IN TWO HOSPITAL SITES IN U.S.
Source text for Eikon: ID:nGNX3sXjbm
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide